Toronto-based PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is expecting to get full approval from the U.S. Food and Drug Administration (FDA) ...
“We live in a “fix-it” culture with an expectation there’s a solution to every problem. But death is not a problem to solve. As has been...
MAPS Public Benefit Corporation (“MAPS PBC”), a company dedicated to transforming mental healthcare, announced an oversubscribed Series A financing....
If you’re interested in becoming a psychedelic therapist, deciding on how to train as one can be a bit of a minefield. There are now many...
Beckley Psytech focuses on short duration psychedelic drug treatments. The post Atai Makes $50 Million Investment Into Beckley Psytech appeared first on...
The firm is targeting the FDA’s 505(b)(2) pathway for a potentially expedited approval process. The post Silo Pharma Proceeds with Ketamine Implant for...
The company is a going concern, with a cumulative deficit of $4,132,349 as of August 31. The post PharmAla Biotech Reports Progress in Earnings appeared...
The firm managed to find adequate research funding over the year as sale talks emerged. The post Tryp Therapeutics Lowers Losses in 2023; Sees New Era...
PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTC: PMBHF)released its audited financial statements in Canadian dollars for the year ended on August 31, 2023....
Microdose takes a look back at some of the top psychedelic stories of 2023. The post The Top Psychedelic Stories of 2023 appeared first on Microdose.